Head & Neck Cancers | Specialty

The OncLive Head and Neck Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with head and neck cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research within head and neck cancer.

Dr Wirth on the Full FDA Approval of Selpercatinib for Advanced RET Fusion+ Thyroid Cancer

June 28th 2024

Lori Wirth, MD, discusses the significance of the full FDA approval of selpercatinib for patients with advanced or metastatic RET fusion+ thyroid cancer.

Ficerafusp Alfa/Pembrolizumab Demonstrates Clinically Meaningful Activity in Metastatic HNSCC

June 27th 2024

The bifunctional antibody ficerafusp alfa plus pembrolizumab generated clinically meaningful activity in HPV–recurrent/metastatic HNSCC.

Dr Olazagasti on Culturally Tailored Lung Cancer Screening for Hispanic Head and Neck Cancer Survivors

June 26th 2024

Coral Olazagasti, MD discusses a tailored lung cancer screening program for Hispanic head and neck cancer survivors.

Dr Sun on Tisotumab Vedotin in Recurrent or Metastatic HNSCC

June 24th 2024

Lova L. Sun, MD, MSCE discusses tisotumab vedotin (in patients with recurrent or metastatic (r/m) head and neck squamous cell carcinoma.

Dr Yilmaz on HB-200 Arenavirus Plus Pembrolizumab in HPV16+ Head and Neck Cancer

June 21st 2024

Emrullah Yilmaz, MD, PhD, discusses HB-200 arenavirus–based immunotherapy plus pembrolizumab in recurrent/metastatic HPV16+ head and neck cancer.

Dr Kirtane on an Investigation of TILs Plus Pembrolizumab in Advanced HNSCC

June 20th 2024

Kedar Kirtane, MD, discusses a phase 1b study of TBio-4101 plus pembrolizumab in patients with PD-1 inhibitor–resistant, advanced HNSCC.

Dr Mattes on the Mechanism of Action of Ipatasertib in HNSCC

June 20th 2024

Malcolm Mattes, MD, discusses the CTEP 10492 trial of ipatasertib plus chemoradiotherapy in locally advanced head and neck squamous cell carcinoma.

Dr Burtness on Subgroup Outcomes for Transoral Surgery and Risk-Based Radiation in HPV+ Oropharynx Cancer

June 14th 2024

Barbara Burtness, MD, discusses findings from a subgroup analysis from the phase 2 E3311 trial in HPV-associated oropharynx cancer.

FDA Grants Full Approval to Selpercatinib for RET+ Thyroid Cancer

June 12th 2024

The FDA granted full approval to selpercatinib for select patients with advanced or metastatic RET fusion–positive thyroid cancer.

Versamune HPV Plus Pembrolizumab Maintains Encouraging OS in Recurrent/Metastatic HPV16+ HNSCC

June 12th 2024

Versamune HPV in combination with pembrolizumab produced a durable median overall survival in patients with recurrent or metastatic HPV16-positive HNSCC.

Dr Mehra on Transoral Surgery and Risk-Based Radiation in HPV+ Oropharynx Cancer

June 10th 2024

Ranee Mehra, MD, discusses long-term results for primary transoral surgery followed by reduced postoperative radiation in HPV-associated oropharynx cancer.

Frontline Petosemtamab Doublet Elicits Responses in Recurrent/Metastatic HNSCC

June 4th 2024

Petosemtamab paired with pembrolizumab had early clinical efficacy when used as first-line treatment in select head and neck squamous cell carcinoma

OncLive’s May Roundup of Key FDA Approvals in Oncology

May 31st 2024

Here is your guide to important regulatory approvals made by the FDA in May 2024.

FDA Grants Accelerated Approval to Selpercatinib for Pediatric RET+ Metastatic Thyroid Cancer or Solid Tumors

May 29th 2024

The FDA has granted accelerated approval to selpercatinib for pediatric patients with select RET-altered metastatic thyroid cancers or solid tumors.

HPV Vaccinations Associated With Lower Rates of HPV-Caused Cancers in Patients Under 40 Years of Age

May 23rd 2024

Patients under the age of 40 who received HPV vaccines were associated with lower rates of HPV-related cancer vs unvaccinated patients.

Tivumecirnon Plus Pembrolizumab Displays Activity and Tolerability in HNSCC

May 20th 2024

Jameel Muzaffar, MD, discusses findings from the phase 2 portion of the FLX475-02 study examining tivumecirnon plus pembrolizumab in HNSCC.

Petosemtamab Receives FDA Breakthrough Therapy Designation in Pretreated HNSCC

May 13th 2024

The FDA has granted breakthrough therapy designation to petosemtamab in recurrent or metastatic head and neck squamous cell carcinoma.

Dr Fox on a Dark Matter–Containing Multivalent Vaccine in Head and Neck Cancer

May 10th 2024

Bernard A. Fox, PhD, discusses an off-the-shelf multivalent vaccine that contains cancer’s dark matter combined with anti–PD-1 and anti-GITR antibodies in head and neck cancer.

Dr Muzaffar on the Evaluation of FLX475 Plus Pembrolizumab in HNSCC

May 10th 2024

Jameel Muzaffar, MD, discusses a study of FLX475 plus pembrolizumab in patients with head and neck squamous cell carcinoma.

First-Line Versamune HPV Plus Pembrolizumab Meets BOR End Point in Recurrent/Metastatic HPV16+ HNSCC

May 10th 2024

First-line treatment with the combination of Versamune HPV and pembrolizumab met a best overall response end point in recurrent/metastatic HNSCC.